Xenon Pharmaceuticals Inc. (XENE)
$55.78
$-0.66
(-1.17%)
As on 11-May-2026 16:07EDT
Market cap
$5,456 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
34.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.7
-
Face value
--
-
Shares outstanding
96,665,550
10 Years Aggregate
CFO
$-466.87 Mln
EBITDA
$-577.53 Mln
Net Profit
$-548.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xenon Pharmaceuticals (XENE)
| 24.5 | -4.5 | 30.8 | 59.3 | 10.7 | 25.2 | 23.7 |
|
BSE Sensex*
| -11.9 | -3.9 | -11.5 | -6.2 | 6.4 | 8.7 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Xenon Pharmaceuticals (XENE)
| 14.3 | 16.8 | 26.2 | 103.1 | 17.3 | 107.8 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xenon Pharmaceuticals (XENE)
|
55.8 | 5,455.8 | 0.0 | -383.2 | -- | -40.4 | -- | 4.1 |
| 15.7 | 1,958.6 | 298.3 | 298.2 | 32.7 | 63.9 | 7.1 | 3.5 | |
| 6.5 | 340.5 | 0.0 | -35.1 | 131,201.1 | -71 | -- | 7.2 | |
| 0.6 | 2.2 | 663.9 | -181.5 | -27.4 | -5.3 | -- | 0.2 |
Shareholding Pattern
View DetailsAbout Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include... Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 Read more
-
President, CEO & Director
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
-
President, CEO & Director
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
-
Headquarters
Burnaby, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Xenon Pharmaceuticals (XENE)
What is the current share price of Xenon Pharmaceuticals Inc (XENE) Today?
The share price of Xenon Pharmaceuticals Inc (XENE) is $55.78 (NASDAQ) as of 11-May-2026 16:07 EDT. Xenon Pharmaceuticals Inc (XENE) has given a return of 10.68% in the last 3 years.
What is the current PB & PE ratio of Xenon Pharmaceuticals Inc (XENE)?
Since, TTM earnings of Xenon Pharmaceuticals Inc (XENE) is negative, P/E ratio is not available.
The P/B ratio of Xenon Pharmaceuticals Inc (XENE) is 4.08 times as on 11-May-2026, a 38 discount to its peers’ median range of 6.58 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.27
|
6.11
|
|
2024
|
-13.11
|
4.07
|
|
2023
|
-17.67
|
3.47
|
|
2022
|
-20.65
|
3.59
|
|
2021
|
-16.31
|
2.34
|
What is the 52 Week High and Low of Xenon Pharmaceuticals Inc (XENE)?
The 52-week high and low of Xenon Pharmaceuticals Inc (XENE) are Rs 63.95 and Rs 28.19 as of 12-May-2026.
What is the market cap of Xenon Pharmaceuticals Inc (XENE)?
Xenon Pharmaceuticals Inc (XENE) has a market capitalisation of $ 5,456 Mln as on 11-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Xenon Pharmaceuticals Inc (XENE)?
Before investing in Xenon Pharmaceuticals Inc (XENE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.